Türkçapar Bariatrics, Obesity Center, İstanbul, Turkey;Department of Health Sciences, Nişantaşı University, İstanbul, Turkey.
Türkçapar Bariatrics, Obesity Center, İstanbul, Turkey.
Turk J Gastroenterol. 2021 Jan;32(1):66-69. doi: 10.5152/tjg.2020.20076.
BACKGROUND/AIMS: The aim of this study is to share the results of gastric botulinum toxin (BTX) application in individuals who are overweight or type 1 obese without comorbidity.
In this study, 13 patients were included who were enrolled for gastric BTX application for the first time. A total of 300 U of BTX-A (Allergan Botox ®1 vial 100 U) was diluted with 8 mL of 0.9% NaCl saline, and antrum (100 U to 8 spots), corpus (100 U to 8 spots), and fundus (100 U to 8 spots) regions were injected intramuscularly. Patients were given a 1200-calorie low-carb diet and this was followed for 6 months.
Gastric BTX application was applied to 13 patients with a mean age of 40.9 ± 5.2 (85% female), a mean body mass index (BMI) of 28.41 ± 1.4 kg/m2 (26-31.6) and a mean excess weight of 10.1 ± 3.6 kg. As a result of the 6-month follow-up, only four patients (30.8%) were able to lose more than 50% of their excess weight (6-15 kg). Six patients (46.2%) could not lose any weight. There was an average decrease of 3.3 kg in the weight of patients before and after BTX application (P = .03). A mean decrease of BMI was detected, 1.17 kg/m2 (P = .032).
It was concluded that the application of gastric BTX for weight loss does not provide effective results.
背景/目的：本研究旨在分享胃内肉毒毒素（BTX）应用于无合并症的超重或 1 型肥胖个体的结果。
本研究纳入了首次接受胃 BTX 应用的 13 例患者。将 1 瓶 100U 的 BTX-A（Allergan Botox ®1 支 100U）稀释至 8ml 0.9%生理盐水，在胃窦（100U 注射 8 个部位）、胃体（100U 注射 8 个部位）和胃底（100U 注射 8 个部位）区域进行肌内注射。患者给予 1200 卡路里低碳水化合物饮食，并持续 6 个月。
胃 BTX 应用于 13 例患者，平均年龄为 40.9 ± 5.2（85%为女性），平均体重指数（BMI）为 28.41 ± 1.4kg/m2（26-31.6），平均超重 10.1 ± 3.6kg。6 个月随访时，仅有 4 例患者（30.8%）能减轻超过 50%的超重（6-15kg）。6 例患者（46.2%）体重无变化。BTX 应用前后患者体重平均减轻 3.3kg（P=0.03）。检测到 BMI 平均降低 1.17kg/m2（P=0.032）。
胃 BTX 应用于减肥效果不佳。
